Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.58 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.58 |
| ▸ | CYP4Z1 | Q86W10 | 3/20 | 0.58 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.58 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PPIB | P23284 | 1/20 | 0.52 |
| ▸ | PPIA | P62937 | 1/20 | 0.52 |
| ▸ | PPID | Q08752 | 1/20 | 0.52 |
| ▸ | PPIG | Q13427 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27741536 | 0.98 | CYP4Z1 (0.57) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL9744594 | 0.95 | CYP4Z1 (0.59) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| Hydrochloric Acid SCHEMBL27344081 | 0.94 | CYP4Z1 (0.58) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL16264858 | 0.94 | CYP4Z1 (0.58) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL10463522 | 0.90 | CYP1A2 (0.59) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL752665 | 0.90 | CYP4F2 (0.72) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| Hydrochloric Acid SCHEMBL11489404 | 0.89 | CYP1A2 (0.58) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| Hydrochloric Acid SCHEMBL6982675 | 0.88 | CYP4F2 (0.70) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL10463270 | 0.87 | CYP1A2 (0.65) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL25567758 | 0.86 | CYP4F2 (0.51) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665800-A1 | NEW CLASS OF DISPERSE AZO DYES, A PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF | Archroma (Switzerland) GmbH (CH) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024170676-A1 | NEW CLASS OF DISPERSE AZO DYES, A PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF | ARCHROMA (SWITZERLAND) GMBH (CH) | 2024-08-22 | — | — | WO | disclosed |
| CN-113979893-B | N-hydroxy formamidine derivative, preparation method and application | 中国药科大学 | 2023-10-24 | — | — | CN | disclosed |
| CN-113979893-A | N-hydroxyformamidine derivative, preparation method and application | 中国药科大学 | 2022-01-28 | — | — | CN | disclosed |
| US-20200148937-A1 | INHIBITING HYDROCARBON HYDRATE AGGLOMERATION | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2020-05-14 | — | — | US | disclosed |
| US-8722723-B2 | Aromatic amide derivative | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2014-05-13 | — | — | US | disclosed |
| US-20110071304-A1 | AROMATIC AMIDE DERIVATIVE | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2011-03-24 | — | — | US | disclosed |
| EP-0946501-B1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER (US) | 2006-05-31 | — | — | EP | disclosed |
| US-6998423-B2 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC. (US) | 2006-02-14 | — | — | US | disclosed |
| US-20040176461-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC | 2004-09-09 | — | — | US | disclosed |
| EP-0045157-B1 | MACROLIDE ANTIBIOTICS, THEIR PREPARATION AND VETERINARY COMPOSITIONS CONTAINING THEM | ELI LILLY AND COMPANY (US) | 1984-04-18 | — | — | EP | disclosed |
| US-4439448-A | IMMUNOMODULATING ACTIVITY | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JP) | 1984-03-27 | — | — | US | disclosed |
| US-4348399-A | Antiatherosclerotic and hypolipidemic 4-(monoalkylamino)phenyl alkane, alkene and alkyne carbinols, aldehydes, carboxylic acids and derivatives | AMERICAN CYANAMID COMPANY (US) | 1982-09-07 | — | — | US | disclosed |
| EP-0052296-A1 | Glutamine derivatives usable for curing immune diseases, methods for their preparation and compositions comprising said derivatives | MITSUBISHI KASEI CORPORATION (JP) | 1982-05-26 | — | — | EP | disclosed |
| US-4318914-A | Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1982-03-09 | — | — | US | disclosed |
| US-4310545-A | Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino) phenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1982-01-12 | — | — | US | disclosed |
| US-4305959-A | Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1981-12-15 | — | — | US | disclosed |
| US-4211783-A | Hypolipidemic and antiatherosclerotic novel 4-(aralkyl- and heteroarylalkylamino)phenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1980-07-08 | — | — | US | disclosed |
| US-4205085-A | Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino)phenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1980-05-27 | — | — | US | disclosed |
| EP-0003663-A2 | Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071304-A1 | AROMATIC AMIDE DERIVATIVE | NCOR2, NCOR1, EP300 | CYP4F2 427/4885CYP4A11 760/4885CYP4Z1 963/4885 |
| US-20040176461-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | HPGDS, PTGIR, PTGER1 | CYP4F2 2453/4885CYP4A11 742/4885CYP4Z1 3767/4885 |
| US-20200148937-A1 | INHIBITING HYDROCARBON HYDRATE AGGLOMERATION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, AHR, SHH | CYP4F2 914/4885CYP4A11 776/4885CYP4Z1 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.